CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment

Kurtz, Jean‐Emmanuel; Buy, Xavier; Deschamps, Frédèric; Sauleau, Erik; Bouhamama, Amine; Toulmonde, Maud; Honoré, Charles; Bertucci, François; Brahmi, Mehdi; Chevreau, Christine; Duffaud, Florence; Gantzer, Justine; Garnon, Julien; Blay, Jean‐Yves; Gangi, Afshin

doi:10.1016/j.ejca.2020.10.035

Cited by 56 publications

(62 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 studies utilised the ½ x (length x width x height) formula [ 20 , 27 ], 1 study utilised the ellipsoid formula [ 22 ], 3 studies utilised manual segmentation [ 23 , 25 , 28 ] and 1 study used IntelliSpace Discovery software platform (Philips Healthcare) semi-automatic 3D segmentation tool [ 26 ]. 1 study did not mention the method of volume measurement [ 24 ].…”

Section: Resultsmentioning

confidence: 99%

“…There was variability in patient selection criteria for cryoablation in the included studies, with some studies only including progressive DT [ 23 , 24 , 27 ], whereas others included DT undergoing cryoablation as first line and >1first line treatment [ 20 – 22 , 25 , 26 , 28 ].…”

Section: Resultsmentioning

confidence: 99%

“…Several studies considered neural structures <1 cm from the tumour margin to be in close proximity [ 25 , 27 , 28 ]. Kurtz et al suggested using CT or MRI, with complementary ultrasound guidance, for at risk procedures [ 24 ]. Saltiel et al recommended a combined ultrasound-guided open surgery approach instead of percutaneous approach for at risk patients [ 25 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Introduction Desmoid tumor is a locally-invasive neoplasm that causes significant morbidity. There is recent interest in cryotherapy for treatment of extra-abdominal desmoid tumors. This systematic review assesses evidence on safety and efficacy of cryotherapy in the treatment of extra-abdominal desmoid tumors. Materials and methods The systematic review was conducted with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Literature search was performed using MEDLINE and the Cochrane Central Register of Controlled Trials. 9 full text papers were reviewed and meta-analysis was performed for measures of safety, efficacy and symptom relief. Results The estimated pooled proportion of major and minor complications was 4.2% (95% CI, 1.8–9.6; I 2 = 0%) and 10.2% (95% CI, 5.7–17.8; I 2 = 0%) respectively. The estimated pooled proportion of non-progressive disease rate of all studies was 85.8% (95% CI, 73.4–93.0; I 2 = 32.9%). The estimated progression free survival rate at 1 year was 84.5% (95% CI:74.6–95.8) and 78.0% at 3 years (95% CI: 63.8–95.3). As for pain control, the estimated pooled proportion of patients with decrease in visual analogue scale (VAS) > = 3 for those with VAS > = 3 before treatment for 2 studies was 87.5% (95% CI, 0.06–100; I 2 = 71.5%) while 37.5% to 96.9% of patients were reported to have experienced partial or complete symptom relief in the other studies. Conclusion Cryotherapy is a safe and effective treatment modality for extra-abdominal desmoid tumors with efficacy similar to those treated with traditional strategies in the short to medium term.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Interestingly, a recent multicenter prospective study showed the possible role of cryotherapy in the treatment of desmoid tumors. In a benign tumor in which only chemotherapy seems to be effective, the possibility of treating this tumor with a minimally invasive method, such as cryotherapy, is an interesting novelty [ 50 ]. Kurtz et al analyzed the use of cryotherapy in 50 patients with non-abdominopelvic progressing desmoid tumors.…”

Section: Main Textmentioning

confidence: 99%

“…Cryotherapy improved functional outcomes and relieved pain. The treatment results of cryotherapy are poor for large tumors [ 50 ]. Following these studies, we suggest a treatment algorithm for desmoid tumors (Fig.…”

Section: Main Textmentioning

confidence: 99%

What’s new in musculoskeletal oncology

Errani

Mavrogenis

Tsukamoto

2021

BMC Musculoskelet Disord

View full text Add to dashboard Cite

We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially in challenging anatomical locations, such as the sacrum and pelvis. Regarding the treatment of giant cell tumor of bone, recent studies have suggested that denosumab administration is related to a higher local recurrence rate following curettage, but a lower local recurrence rate following en bloc resection. In addition, there was no difference in the local recurrence rate at five years after surgery between short-term and long-term denosumab therapy. With regard to soft tissue tumors, percutaneous cryoablation appears to be a new treatment option for extra-abdominal desmoid tumors, with encouraging results. Regarding soft tissue sarcomas, a negative surgical margin of < 1 mm is sufficient to control local recurrence. Pexidartinib seems to be a promising systemic therapy for the treatment of tenosynovial giant cell tumors for which surgery is not expected to improve the function of the affected limb. Finally, the life expectancy of patients is the most important factor in determining the optimal surgical procedure for patients with impending or pathological fractures of the long bone due to metastatic bone tumors. Elevated C-reactive protein level was found to be an independent poor prognostic factor at 1 year after surgery for long bone metastases.

show abstract

Current Management of Desmoid Tumors

Kasper,

Baldini,

Bonvalot

et al. 2024

JAMA Oncol

Self Cite

View full text Add to dashboard Cite

ImportanceDesmoid tumor (DT) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been made. To update the 2020 global evidence-based consensus guideline on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus meeting in Milan, Italy, on June 30, 2023, under the auspices of the European Reference Network on Rare Adult Solid Cancers and Sarcoma Patient Advocacy Global Network, the Desmoid Foundation Italy, and the Desmoid Tumor Research Foundation. The meeting brought together over 90 adult and pediatric sarcoma experts from different disciplines as well as patients and patient advocates from around the world.ObservationsThe 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors. Literature searches of MEDLINE and Embase databases were performed for English-language randomized clinical trials (RCTs) of systemic therapies to obtain data to support the consensus recommendations. Of the 18 full-text articles retrieved, only 4 articles met the inclusion criteria. The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery; and the γ-secretase inhibitor nirogacestat, the first representative of the newest class of medical agents and first approved drug for DT. Management of DT is complex and should be carried out exclusively in designated DT referral centers equipped with a multidisciplinary tumor board. Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.Conclusions and RelevanceThe therapeutic armamentarium of DT therapy is continually expanding. It is imperative to carefully select the management strategy for each patient with DT to optimize tumor control and enhance quality of life.

show abstract

CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment

Cited by 56 publications

References 29 publications

Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis

Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis

What’s new in musculoskeletal oncology

Current Management of Desmoid Tumors

Contact Info

Product

Resources

About